Epizyme, Genentech, Roche deal

Roche’s Genentech unit and Epizyme partnered to conduct a Phase Ib trial to evaluate Epizyme’s tazemetostat and Genentech’s Tecentriq atezolizumab to treat relapsed or refractory diffuse large B cell lymphoma (DLBCL). The partners will provide their respective products and equally share costs for the trial, which is slated to begin next half. A joint development committee will monitor the trial, and Genentech will manage it. ...